Rozdiely v incidencii a biologických charakteristikách karcinómu prsníka medzi rómskymi a nerómskymi pacientkami na Slovensku
Authors:
M. Reckova 1,2; J. Mardiak 1; L. Plank 3; M. Vulevova 4; S. Cingelova 1; M. Mego 1
Authors‘ workplace:
nd Department of Medical Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovak Republic
1; POKO Poprad, s. r. o., Slovak Republic
2; Department of Pathology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic
3; Department of Pharmacy, Comenius University in Bratislava, Slovak Republic
4
Published in:
Klin Onkol 2017; 30(1): 48-54
Category:
Original Articles
doi:
https://doi.org/10.14735/amko201748
Overview
Východiská:
Rómovia tvoria jednu z najväčších etnických minorít na Slovensku. Existujú údaje o vyššej prevalencii prenosných ochorení u Romov, zaťiaľčo údaje o nádorových ochoreniach v rómskej populácii známe nie sú. Cieľom tejto štúdie bolo porovnať rozdiely v incidencii a patologických charakteristikách medzi rómskymi a nerómskymi pacientkami s nádorom prsníka na Slovensku. Materiál a metódy: Na základe údajov o pohlaví, dátumu narodenia a bydliska sme spárovali databázu HER2 registra v rokoch 2011–2013 s posledným sčítaním ľudu Slovenskej republiky v roku 2011, a identifikovali sme rómske a nerómske pacientky s karcinómom prsníka. Výsledky: Identifikovali sme 32 rómskych a 5 775 nerómskych pacientok s karcinómom prsníka. Vekovo-štandardizovaná incidencia karcinómu prsníka bola 2,12-krát vyššia u nerómiek v porovnaní s rómkami (36 vs. 17 na 100 000 ľudí). Rómky boli v čase diagnózy mladšie v porovnaní s neRómkami (medián 49 vs. 61 rokov; p = 0,00001). Rómky mali v porovnaní s nerómkami viac hormón-receptor negatívnych (34,4 vs. 18,1 %; p = 0,03) a triple-negatívnych nádorov (28,1 vs. 12,3 %; p = 0,01), a tieto rozdiely zostali štatisticky signifikantné v multivariačnej analyze. Záver: Poprvykrát sme zistili rozdiely v incidencii a biologických charakteristikách u rómskych žien s karcinómom prsníka v porovnaní s nerómskymi pacientkami. Na základe zistených údajov predpokladáme, že rómske pacientky s karcinómom prsníka sú mladšie v čase diagnózy, majú nižšiu vekovo-štandardizovanú incidenciu a biologicky agresívnejšie nádory v porovnaní s nerómkami.
Kľúčové slová:
nádory prsníka – incidencia – Rómovia – epidemiológia
M. R., J. M., S. C. a M. M. deklarujú, že v súvislosti s predmetom štúdie nemajú žiadne komerčné záujmy. L. P. je odborný garant, zamestnaný a spolumajiteľ Martinského bioptického centra, s.r.o.; v minulosti dostal finančnú odmenu od spoločnosti Roche Slovensko. M. V. bola v posledných 2 rokoch zamestnaná v spoločnosti Roche Slovensko.
Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.
Obdrženo:
29. 8. 2016
Přijato:
26. 10. 2016
Sources
1. Koupilová I, Epstein H, Holcík J et al. Health needs of the Roma population in the Czech and Slovak Republics. Social Science Medicine 2001; 53 (9): 1191–1204.
2. Musinka A, Skobla D, Hurrle J et al. Atlas of Roma Communities in Slovakia 2013 [monograph on Internet]. United Nations Development Programme; 2014 [cited 2016 Jul 1]. Available from: http: //www.minv.sk/?atlas_2013.
3. Matlovicova K, Matlovic R, Musinka A et al. The Roma population in Slovakia. Basic characteristics of the Roma population with emphasis on the spatial aspects of its differentiation. In: Penczse J, Radics Z (eds). Roma population on the peripheries of the Visegrad countries. Spatial Trends and social challenges. Debrecen 2012: 77–104.
4. Parekth N, Rose T. Health inequalities of the Roma in Europe: a literature review. Centr Eur J Public Health 2011; 19 (3): 139–142.
5. Cook B, Wayne FG, Valentine A et al. Revisiting the evidence on health and health disparities among the Roma: a systematic review 2003–2012. In J Public Health 2013; 58 (6): 885–911. doi: 10.1007/s00038-013-0518-6.
6. Rosicova K, Reijneveld SA, Madarasova-Geckova A et al. Inequalities in mortality by socioeconomic factors and Roma ethnicity in the two biggest cities in Slovakia: a multilevel analysis. International J Equity Health 2015; 14 (1): 123. doi: 10.1186/s12939-015-0262-z.
7. Rosicova K, Madarasova-Geckova A, van Dijk JP et al. Regional socioeconomic indicators and ethnicity as predictors of regional infant mortality rate in Slovakia. Int J Public Health 2011; 56 (5): 523–531. doi: 10.1007/s00038-010-0199-3.
8. Casals M, Pila P, Langohr K et al. Incidence of infectious diseases and survival among the Roma population: a longitudinal cohort study. Eur J Public Health 2011; 22 (2): 262–266. doi: 10.1093/eurpub/ckq204.
9. Chalupa P, Jezek P, Privorova A et al. Viral hepatitis A in the catchment area of the Brno University Hospital 1983–1990. Cesk Epidemiol Mikrobiol Imunol 1992; 41 (1): 2–7.
10. Gyarmarthy VA, Neaigus A, Ujhelyi E. Vulnerability to drug-related infections and co-infections among injecting drug users in Budapest, Hungary. Eur J Public Health 2009; 19 (3): 260–265. doi: 10.1093/eurpub/ckp009.
11. Vantarakis A, Nearxou A, Pagonidis D et al. An outbreak of hepatitis A in Roma populations living in three prefectures in Greece. Epidemiol Infect 2010; 138 (7): 1025–1031. doi: 10.1017/S0950268809991257.
12. Kojouharova M, Zuber PL, Gyurova S et al. Importation and circulation of poliovirus in Bulgaria in 2001. Bul World Health Organ 2003; 81 (7): 476–481.
13. Maduma-Butshe A, McCarthy N. The burden and impact of measles among the Gypsy-Traveller communities, Thames Valle, 2006-09. J Public Health 2013; 35 (1): 27–31. doi: 10.1093/pubmed/fds052.
14. Dostal M, Topinka J, Sram RJ. Comparison of the health of Roma and non-Roma children living in the district of Teplice. Int J Public Health 2010; 55 (5): 435–441. doi: 10.1007/s00038-010-0133-8.
15. Monasta L, Andersson N, Ledogar RJ et al. Minority health and small numbers epidemiology: a case study of living conditions and the health of children in 5 foreign Roma camps in Italy. Am J Public Health 2008; 98 (11): 2035–2041. doi: 10.2105/AJPH.2007.129734.
16. Teira R, Suarez-Lozano I, Lozano F et al. Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort. Enferm Infecc Microbiol Clin 2010; 28 (5): 266–272. doi: 10.1016/j.eimc.2009.04.018.
17. Hidvegi T, Hetyesi K, Biro L et al. Screening for metabolic syndrome within a minority ethnic group (adult Gypsy people) in Hungary. Bratisl Lek Listy 2011; 113 (12): 721–724.
18. Vozarova de Courten B, de Courten M, Hanson RL et al. Higher prevalence of type 2 diabetes, metabolic syndrome and cardiovascular diseases in gypsies than in non-gypsies in Slovakia. Diabetes Res Clin Pract 2003; 62 (2): 95–103.
19. Zivkovic TB, Marjanovic M, Prgomelja S et al. Screening for diabetes among Roma people living in Serbia. Croat Med J 2010; 51 (2): 144–150.
20. Zjelko HM, Skaric-Juric T, Narancic NS et al. Traditional CVD risk factors and socio-economic deprivation in Roma minority population of Croatia. Coll Antropol 2008; 32 (3): 667–676.
21. Gualdi-Russo E, Zironi A, Dallari GV et al. Migration and health in Italy: a multiethnic adult sample. J Travel Med 2009; 16 (2): 88–95. doi: 10.1111/j.1708-8305.2008.00 280.x.
22. Carrasco-Garrido P, Lopez de Andrés AL, Hernandez Barrera VH et al. Health status of Roma women in Spain. Eur J Public Health 2011; 21 (6): 793–798. doi: 10.1093/eurpub/ckq153.
23. Ginter E, Krajcovicova-Kudlackova M, Kacala O et al. Health status of Romanies (Gypsies) in the Slovak Republic and in the neighboring countries. Bratisl Lek Listy 2001; 102 (10): 479–484.
24. Brawley OW. Health disparities in breast cancer. Obstet Gynecol Clin North Am 2013; 40 (3): 513–523. doi: 10.1016/j.ogc.2013.06.001.
25. Grenae C, Phelps MA, Villalona-Calero MA. Race and ethnicity in cancer therapy: what have we learned? Clin Pharm Therap 2014; 95 (4): 403–412. doi: 10.1038/clpt.2014.5.
26. Newman LA. Breast cancer disparities: high-risk breast cancer and African ancestry. Surg Oncol Clin N Am 2014; 23 (3): 579–592. doi: 10.1016/j.soc.2014.03.014.
27. Dressler WW, Oths KS, Gravlee CC. Race and ethnicity in public health research: models to explainhealth disparities. Annu Rev Anthropol 2005; 34: 231–252.
28. Collins Y, Holcomb K, Chapman-Davis E et al. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecol Oncol 2014; 133 (2): 353–361. doi: 10.1016/ j.ygyno.2013.12.039.
29. Powel IJ. Prostate cancer in the African American: is this a different disease? Semin Urol Oncol 1998; 16 (4): 221–226.
30. Joshi AD, John EM, Koo J et al. Fish intake, cooking practices, and risk of prostate cancer: results from a multi-ethnic case-control study. Cancer Causes Control 2012; 23 (3): 405–420. doi: 10.1007/s10552-011-9889-2.
31. Reddy S, Shapiro M, Morton R et al. Prostate cancer in black and white Americans. Cancer Metastasis Rev 2003; 22 (1): 83–86.
32. Graham-Steed T, Uchio E, Wells CK et al. Race and prostate cancer mortality in equal-access healthcare systems. Am J Med 2013; 126 (12): 1084–1088. doi: 10.1016/ j.amjmed.2013.08.012.
33. Cykert S, Dilworth-Anderson P, Monroe MH et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 2010; 303 (23): 2368–2376. doi: 10.1001/jama.2010.793.
34. Lathan CS, Neville BA, Earle CC. The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol 2006; 24 (3): 413–418.
35. Gordon HS, Street RL Jr, Sharf BF et al. Racial differences in doctors’ information-giving and patients’ participation. Cancer 2006; 107 (6): 1313–1320.
36. DeDeugd C, Miyake M, Palacios DA et al. The influence on race on overall survival in patients with newly diagnosed bladder cancer. J Racial Ethn Health Disparities 2015; 2 (1): 124–131.
37. Samson ME, Porter NG, Hurley DM et al. Disparities in breast cancer incidence, mortality, and quality of care among African American and European American women in South Carolina. South Med J 2016; 109 (1): 24–30. doi: 10.14423/SMJ.0000000000000396.
38. Diez O, Doménech M, Alonso MC et al. Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population. Hum Genet 1998; 103 (6): 707–708.
39. Krajcovicova I, Diba SC, Sieberova G et al. Cancer incidence in the Slovak Republic 2009 [monograph on the Internet]. National Health Information Center, National Cancer Registry Bratislava; 2015 [cited 2016 Jul 1]. Available from: http: //www.nczisk.sk/Documents/publikacie/analyticke/incidencia_zhubnych_nadorov_2009.pdf.
40. Popper M, Szeghy P, Sarkozy S. Health and the Roma community: Analysis of the situation in Europe [monograph on Internet]. Partners for Democratic Change Slovakia 2009 [cited 2016 Jul 1]. Available from: http: //www.gitanos.org/upload/13/60/Eslovaquia-corrected.pdf.
41. DeSantis C, Siegel R, Jemal A. American Cancer Society. Breast Cancer Facts & Figures 2015–2016 [monograph on Internet]. American Cancer Society, Inc.; 2015. [cited 2016 Jul 1]. Available from: http: //www.cancer.org/acs/groups/content/@research/documents/document/acspc-046381.pdf.
42. Smigal C, Jemal A, Ward E et al. Trends in cancer by race and ethnicity: Update 2006. CA Cancer J Clin 2006; 56 (3): 168–183.
43. Sobin LH, Gospodarowicz MK, Wittekind CH (eds). TNM classification of malignant tumors. 7th ed. Wiley-Blackwell 2009: 1–336.
44. Novak J, Fabian P. Comments on the TNM classification of malignant tumors – 7th edition. Klin Onkol 2011; 24 (2): 149–150.
45. Rosenthal E, Moves K, Arnell C et al. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat 2015; 149 (1): 223–227. doi: 10.1007/s10549-014-3218-x.
46. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24 (9) : 2206–2223. doi: 10.1093/annonc/mdt303.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2017 Issue 1
Most read in this issue
- Lymfedém po operacích na spádových lymfatických uzlinách pro karcinom prsu
- Epitelo-mezenchymální tranzice v nádorové tkáni a její role při metastatickém šíření karcinomů
- Daratumumab – naděje pro myelomové pacienty, výzva pro klinické laboratoře
- Možnosti chemoterapie v léčbě karcinomu prostaty